Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mirati Therapeutics (MRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,949,690
  • Shares Outstanding, K 32,360
  • Annual Sales, $ 0 K
  • Annual Income, $ -70,430 K
  • 36-Month Beta 1.95
  • Price/Sales 205.88
  • Price/Cash Flow N/A
  • Price/Book 7.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.84
  • Number of Estimates 4
  • High Estimate -0.77
  • Low Estimate -0.88
  • Prior Year -0.65
  • Growth Rate Est. (year over year) -29.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.60 +17.19%
on 09/07/18
61.70 -3.89%
on 09/21/18
+2.40 (+4.22%)
since 08/21/18
3-Month
45.80 +29.48%
on 06/28/18
65.35 -9.25%
on 07/31/18
+6.90 (+13.17%)
since 06/21/18
52-Week
9.55 +520.94%
on 09/25/17
65.35 -9.25%
on 07/31/18
+48.95 (+472.95%)
since 09/21/17

Most Recent Stories

More News
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (PTCT , TTOO, SGMO , PBYI , MRTX)

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

PTCT : 45.14 (-2.53%)
SGMO : 15.75 (-1.25%)
TTOO : 6.32 (+1.44%)
MRTX : 59.30 (-1.58%)
Mirati Therapeut Up 79.0% Since SmarTrend Uptrend Call (MRTX)

SmarTrend identified an Uptrend for Mirati Therapeut (NASDAQ:MRTX) on April 17th, 2018 at $31.65. In approximately 5 months, Mirati Therapeut has returned 78.99% as of today's recent price of $56.65.

MRTX : 59.30 (-1.58%)
81.0% Return Seen to Date on SmarTrend Mirati Therapeut Call (MRTX)

SmarTrend identified an Uptrend for Mirati Therapeut (NASDAQ:MRTX) on April 17th, 2018 at $31.65. In approximately 4 months, Mirati Therapeut has returned 81.04% as of today's recent price of $57.30.

MRTX : 59.30 (-1.58%)
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

Style Box ETF report for DWAS

DWAS : 57.57 (-0.76%)
CDNA : 25.95 (+0.35%)
MRTX : 59.30 (-1.58%)
PLUS : 94.00 (-2.03%)
Mirati Therapeutics Reaches Analyst Target Price

In recent trading, shares of Mirati Therapeutics Inc have crossed above the average analyst 12-month target price of $57.50, changing hands for $58.25/share. When a stock reaches the target an analyst...

MRTX : 59.30 (-1.58%)
Mirati Therapeut Has Returned 81.4% Since SmarTrend Recommendation (MRTX)

SmarTrend identified an Uptrend for Mirati Therapeut (NASDAQ:MRTX) on April 17th, 2018 at $31.65. In approximately 4 months, Mirati Therapeut has returned 81.36% as of today's recent price of $57.40.

MRTX : 59.30 (-1.58%)
Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced that a KRAS G12C poster will be presented by scientists from Mirati and Array BioPharma at the 255th...

MRTX : 59.30 (-1.58%)
Uptrend Call Working As Mirati Therapeut Stock Rises 77.6% (MRTX)

SmarTrend identified an Uptrend for Mirati Therapeut (NASDAQ:MRTX) on April 17th, 2018 at $31.65. In approximately 4 months, Mirati Therapeut has returned 77.57% as of today's recent price of $56.20.

MRTX : 59.30 (-1.58%)
Mirati: 2Q Earnings Snapshot

SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Wednesday reported a loss of $27.9 million in its second quarter.

MRTX : 59.30 (-1.58%)
Mirati Therapeutics Reports Second Quarter Financial Results

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter ended June 30, 2018.

MRTX : 59.30 (-1.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade MRTX with:

Business Summary

Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada.

See More

Key Turning Points

2nd Resistance Point 63.57
1st Resistance Point 61.43
Last Price 59.30
1st Support Level 57.43
2nd Support Level 55.57

See More

52-Week High 65.35
Last Price 59.30
Fibonacci 61.8% 44.03
Fibonacci 50% 37.45
Fibonacci 38.2% 30.86
52-Week Low 9.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar